Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 2, pp 282–285 | Cite as

Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring

  • Maria SwartlingEmail author
  • Reetu Gupta
  • Vicky Dudas
  • B. Joseph Guglielmo
Short Research Report

Abstract

Background After medical center implementation of 2009 ASHP/IDSA guidelines, we evaluated the appropriateness of vancomycin dosing and TDM. Objective Our primary objectives were to assess short term effects on (1) appropriateness of initial vancomycin dosing, (2) appropriateness of sampling of plasma levels, before and after implementation of guidelines. Method The study was conducted in two phases, pre-guideline and post-guideline implementation. The interventions included (1) Nurses and phlebotomist education regarding the appropriate timing of vancomycin sampling, (2) A nomogram for appropriate initial dosing that was distributed to medical staff. Patient demographics, dosing and timing of sampling were collected in eligible patients and assessed for appropriateness. Results The appropriateness of the prescribed dose increased from 51% (128/253) of patients during the pre period to 78% (155/200) (p < 0.0001) during the post period. Similarly, overall appropriateness of sampling of vancomycin troughs at steady state improved from 36% (63/173) pre to 55% (106/191) (p < 0.03) post. Specifically, the appropriate timing of troughs (within 30 min of the next dose) increased from 37% (64/173) during the pre period to 78% (149/191) during the post period (p < 0.0001). Conclusion Adoption of the guidelines with associated training resulted in significant short term improvement in vancomycin dosing and TDM

Keywords

Appropriate use Education Guidelines Therapeutic drug monitoring TDM Vancomycin 

Notes

Funding

MS was supported by Swedish Academy of Pharmaceutical Sciences.

Conflicts of interest

None.

References

  1. 1.
    Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006;368(9538):874–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clin Infect Dis. 2008;46(11):1637–46.PubMedCrossRefGoogle Scholar
  3. 3.
    Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46(Suppl 5):S360–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009;22(4):352–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health-Syst Pharm. 2009;66(1):82–98.PubMedCrossRefGoogle Scholar
  6. 6.
    Hall RG II, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121(6):515–8.PubMedCrossRefGoogle Scholar
  7. 7.
    de Castro MS, Kopittke L, Fuchs FD, Tannhauser M. Evidence of inappropriate use of vancomycin in a university affiliated hospital in Brazil. Pharmacoepidemiol Drug Saf. 1999;8(6):405–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodman DP, McKnight JT, Rogers T, Robbins M. The appropriateness of initial vancomycin dosing. J Fam Pract. 1994;38(5):473–7.PubMedGoogle Scholar
  9. 9.
    Carroll DJ, Austin GE, Stajich GV, Miyahara RK, Murphy JE, Ward ES. Effect of education on the appropriateness of serum drug concentration determination. Ther Drug Monit. 1992;14(1):81–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Maria Swartling
    • 1
    Email author
  • Reetu Gupta
    • 2
  • Vicky Dudas
    • 3
  • B. Joseph Guglielmo
    • 2
  1. 1.Department of Pharmaceutical BiosciencesUppsala UniversityUppsalaSweden
  2. 2.Department of Clinical Pharmacy, School of PharmacyUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Department of Pharmaceutical ServicesUniversity of California San Francisco Medical CenterSan FranciscoUSA

Personalised recommendations